GLP-1 Drugs and Pregnancy: When to Stop and What to Know

GLP-1 medications are being used by millions of women of reproductive age. For anyone planning a pregnancy - or open to the possibility - understanding the guidance around these drugs is important.

The main message is clear: stop GLP-1 medication before trying to conceive, and do not use it during pregnancy or breastfeeding.

Why GLP-1 drugs should be stopped before pregnancy

GLP-1 medications have not been studied in human pregnancies, and they are not approved for use during pregnancy. This is not because they have been proven harmful - it is because there is simply not enough safety data.

What we do know:

Animal studies showed developmental risks. Reproductive toxicity studies in rats and rabbits using semaglutide and tirzepatide showed effects including reduced fetal growth, skeletal abnormalities, and increased fetal deaths at doses relevant to human therapeutic exposure. These findings are standard triggers for pregnancy contraindications in drug labelling.

GLP-1 receptors are present in fetal tissue. GLP-1 receptors play a role in fetal organ development. Artificially activating these receptors during pregnancy could theoretically interfere with normal development, though this has not been confirmed in human data.

The precautionary principle applies. Until large-scale human pregnancy data exists, the reasonable and responsible approach is to avoid exposure.

When to stop: the timing guidance

All major GLP-1 prescribing information recommends stopping the medication at least two months before attempting conception.

Why two months? Semaglutide has a half-life of approximately one week. After the last injection, meaningful drug levels persist for several weeks. Two months provides adequate clearance to ensure drug exposure is minimal at the time of conception.

The same two-month guideline applies to tirzepatide (half-life approximately 5 days, slightly shorter than semaglutide).

For oral GLP-1 medications (Wegovy pill, Rybelsus)

Daily oral medications have shorter half-lives. However, the same two-month pre-conception stoppage period is advisable for consistency and safety. Your doctor may advise a shorter period depending on specific circumstances.

What happens to your body when you stop

Be prepared for:

• Return of appetite. GLP-1 suppression of hunger reverses within days of stopping. Some people experience significant rebound hunger.
• Weight regain risk. Without the medication, weight may start returning. Have a plan with your doctor for managing this during the pre-conception and pregnancy period.
• Blood sugar changes (if you have diabetes). Work with your doctor to transition to pregnancy-safe diabetes management.

Can GLP-1 improve fertility before you stop?

Yes - in some cases. For women with PCOS or insulin resistance, weight loss and improved hormonal balance from GLP-1 therapy may:

• Restore more regular menstrual cycles
• Improve ovulation frequency
• Reduce androgen levels (which can interfere with conception)

This means GLP-1 therapy used beforehand - then stopped at the right time - can sometimes improve fertility prospects before conception is attempted.

Discuss this timing strategy with your gynaecologist or reproductive endocrinologist.

What to do if you discover you are pregnant while on GLP-1

1. Stop the medication immediately
2. Contact your doctor promptly
3. Report the exposure - Novo Nordisk (1-833-NOVO-411) and Eli Lilly (1-800-545-5979) both maintain pregnancy registries to track outcomes in women inadvertently exposed
4. Do not panic - single-trimester exposure at therapeutic doses has not been demonstrated to cause human harm, but monitoring is prudent

Breastfeeding

Current guidance recommends not using GLP-1 medications while breastfeeding. It is unknown whether semaglutide or tirzepatide passes into breast milk in meaningful amounts, or whether it could affect a nursing infant. The precautionary recommendation is to avoid use until after breastfeeding has stopped.

Planning the transition

If you are on GLP-1 therapy and planning a pregnancy within the next 6–12 months, the conversation with your doctor should cover:

• The two-month stoppage timeline relative to your conception plans
• Management of weight, blood sugar, or PCOS during the medication-free period
• Whether low-dose maintenance closer to the time is appropriate in your case
• Nutritional support during pregnancy (protein, folate, iron, DHA)
• A plan for restarting GLP-1 after breastfeeding ends

Final takeaway

GLP-1 medications should be stopped at least two months before trying to conceive. They are not approved during pregnancy or breastfeeding due to insufficient safety data and animal study findings. Many women use GLP-1 therapy beneficially before pregnancy - particularly for PCOS and weight management - then stop at the right time. Plan the transition carefully with your doctor.

Consult your healthcare provider about timing and transition planning specific to your situation.

Sources

• Ozempic prescribing information - pregnancy and lactation sections (Novo Nordisk)
• Wegovy prescribing information - Novo Nordisk
• Zepbound prescribing information - Eli Lilly
• Mounjaro prescribing information - Eli Lilly
• Novo Nordisk pregnancy registry: 1-833-NOVO-411
• Eli Lilly pregnancy registry: 1-800-545-5979